The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 5, 2008, Pages 976-983

  Igerc, I ^a   Kohlfurst S ^a   Gallowitsch, H J ^a   Matschnig, S ^a   Kresnik, E ^a   Gomez Segovia, I ^a   Lind, P ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

18F choline; PET CT; Prostate cancer; TRUS guided prostate biopsy

Indexed keywords

FLUOROCHOLINE F 18; IASOCHOLINE; IODIXANOL; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROCHOLINE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MEDICAL EXAMINATION; NEEDLE BIOPSY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; TRANSRECTAL ULTRASONOGRAPHY; WHOLE BODY CT; WHOLE BODY PET; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY, NEEDLE; CHOLINE; FALSE NEGATIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 42149146929     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0686-9     Document Type: Article

References (32)

1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-64.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-61. Erratum in: N Engl J Med 1991;325(18):1324.
3. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Pt 2):841-5.
4. Roscigno M, Scattoni V, Bertini R, Pasta A, Montorsi F, Rigatti P. Diagnosis of prostate cancer. State of the art. Minerva Urol Nefrol. 2004;56(2):123-45.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
6. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol. 1995;153(5):1496-8.
7. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol. 1997;158(2):505-8. discussion 508-9.
8. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998 Apr;159(4):1247-50.
9. Kravchick S, Cytron S, Peled R, Altshuler A, Ben-Dor D. Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer. Urology. 2003;61(5):977-81.
10. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999;213(2):473-80.
11. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol. 1998;159(2):347-56.
12. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199(3):751-6. Jun.
13. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39(6):990-5.
14. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296(3):580-3.
15. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999 Jan 1;59(1):80-4.
16. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273-80.
17. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163(3):806-12.
18. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151(6):1571-4.
19. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5(5):303-24.
20. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, Morishita Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999;90(4):419-24.
21. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61(1):110-7.
22. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43(1):92-6.
23. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47(2):262-9.
24. Hakalahti L, Vihko P, Henttu P, Autio-Harmainen H, Soini Y, Vihko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer. 1993;55(4):590-7.
25. Wyss MT, Weber B, Honer M, Spath N, Ametamey SM, Westera G, et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004;43:187-99.
26. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235(2):623-8.
27. True LD, Berger RE, Rothman I, Ross SO, Krieger JN. Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol. 1999;162(6):2014-8.
28. Shukla-Dave A, Hricak H, Eberhardt SC, Olgac S, Muruganandham M, Scardino PT, et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology. 2004;231(3):717-24.
29. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol. 2002;4(4):267-73.
30. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31(3):317-24.
31. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of (11)C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(1):45-53.
32. Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, Glode LM. Prostate cancer pathology, screening, and epidemiology. Rev Urol. 2001;3(Suppl2):S2-S10.